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Abstract
Background: Antipsychotic drugs can negatively affect the metabolic status of patients, with olanzapine as one of the most 
potent drugs. While patients are often medicated for long time periods, experiments in rats typically run for 1 to 12 weeks, 
showing olanzapine-related weight gain and increased plasma lipid levels, with transcriptional upregulation of lipogenic 
genes in liver and adipose tissue. It remains unknown whether metabolic status will deteriorate with time.
Methods: To examine long-term metabolic effects, we administered intramuscular long-acting injections of olanzapine 
(100 mg/kg BW) or control substance to female rats for up to 13 months.
Results: Exposure to olanzapine long-acting injections led to rapid weight gain, which was sustained throughout the 
experiment. At 1, 6, and 13 months, plasma lipid levels were measured in separate cohorts of rats, displaying no increase. 
Hepatic transcription of lipid-related genes was transiently upregulated at 1  month. Glucose and insulin tolerance tests 
indicated insulin resistance in olanzapine-treated rats after 12 months.
Conclusion: Our data show that the continuous increase in body weight in response to long-term olanzapine exposure was 
accompanied by surprisingly few concomitant changes in plasma lipids and lipogenic gene expression, suggesting that 
adaptive mechanisms are involved to reduce long-term metabolic adverse effects of this antipsychotic agent in rats.
Keywords: olanzapine, weight gain, diabetes, long-term, rat
Introduction
The global lifetime prevalence of schizophrenia, a serious psych-
otic disorder, approximates 0.7% (McGrath et al., 2008). Patients 
diagnosed with schizophrenia may experience different illness 
trajectories with varying incidence of psychotic episodes, but 
a significant number of patients require long-term treatment 
with antipsychotic medication (Bowtell et al., 2017; Wunderink, 
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2017). Many second-generation antipsychotic drugs that are 
commonly used have serious metabolic adverse effects such 
as weight gain, dyslipidemia, and type 2 diabetes (Correll et al., 
2015). The second-generation antipsychotic drugs olanzapine 
and clozapine are associated with particularly high risk, but are 
also regarded as clinically efficacious and valuable drugs (Leucht 
et  al., 2013; Correll et  al., 2015). To prevent metabolic adverse 
effects and aid drug development, uncovering the underlying 
molecular mechanisms is pivotal. Propensity for weight gain 
correlates with affinity of antipsychotic agents for serotonin 
5HT2C and histamine H1 receptors, while binding to peripheral 
muscarinic M3 receptors has been linked to diabetes (Kroeze 
et al., 2003; Reynolds and Kirk, 2010). However, much remains 
unknown with regard to downstream and possible receptor-
independent mechanisms.
Preclinical studies, which can be performed in a controlled 
environment and also grant access to biological samples not 
available in clinical studies, are valuable in this context. In the 
female rat, antipsychotic-induced metabolic adverse effects 
such as hyperphagia, weight gain, increased serum lipids, 
and glucose dysregulation have been extensively reproduced 
(Boyda et al., 2010; Benarroch et al., 2016). For some dysmeta-
bolic features, molecular mechanisms have been suggested. 
For instance, olanzapine-induced hyperphagia has been linked 
to activation of hypothalamic AMP-activated kinase and upreg-
ulation of orexigenic neuropeptides in the hypothalamus (Kim 
et  al., 2007; Ferno et  al., 2011; Skrede et  al., 2014). Although 
increased serum cholesterol and triglycerides correlate with 
activation of the key lipogenic transcription factors sterol regu-
latory element binding proteins 1 and 2 in peripheral tissues, 
causality has yet to be established (Skrede et al., 2012b; Skrede 
et al., 2014).
The gap between the observed metabolic adverse effects of 
antipsychotic drugs and the underlying molecular mechanisms 
still needs to be bridged. Establishing a valid animal model has 
proved challenging (Benarroch et al., 2016). As an example, the 
average half-life of olanzapine in rats is short—2.5 hours, com-
pared with 33 hours in humans (Aravagiri et al., 1999). In many 
rat experiments, olanzapine has been administered 2 or 3 times 
a day, but markedly fluctuating drug concentrations throughout 
the day has represented a major confounder. Owing to the dif-
ficulty in achieving steady-state conditions, in addition to 
the significant workload associated with drug administration 
at least twice a day, most rat studies have lasted for 1 to 12 
weeks (Han et al., 2008; Boyda et al., 2010; Skrede et al., 2012a). 
As an alternative to repeated daily drug administrations, pre-
vious experiments have also involved exposure to olanzapine 
for up to 8 weeks by means of subcutaneously implanted os-
motic minipumps, ensuring stable delivery of drug amounts 
corresponding to clinically relevant dopamine D2 receptor oc-
cupancy (Kapur et al., 2003; Mondelli et al., 2013; Calevro et al., 
2018). Unfortunately, the duration of experiments is limited by 
the fact that minipumps have to be exchanged every 2 weeks, 
with a limited number of pump exchanges regarded as ethically 
and practically feasible (Remington et  al., 2011). We and oth-
ers have recently described how the use of long-acting injec-
tions (LAI) of olanzapine can yield stable plasma concentrations 
and relevant metabolic phenotypes (Saeedi et al., 2007; Skrede 
et al., 2014; Ersland et al., 2015; Ferno et al., 2015; Horska et al., 
2016). This development paves the way for long-term studies in 
the rat, which could clarify whether metabolic adverse effects 
of olanzapine will become more pronounced with prolonged 
exposure times.
Using a treatment scheme with biweekly intramuscular 
injections of long-acting olanzapine, we treated female rats 
for 13 months, roughly corresponding to 26 years of human 
life (Sengupta, 2013), with frequent measurements of body 
weight throughout the experiment. Female rats were cho-
sen due to the fact that the clinically relevant phenotype of 
weight gain is readily reproduced in female rats, unlike in 
male rats (Boyda et  al., 2010; Ferno et  al., 2015). In a long-
term experiment, this facilitates noninvasive monitoring of 
the metabolic phenotype. Separate cohorts of rats were sac-
rificed after 1, 3, 6, and 13 months of treatment, followed by 
measurements of plasma olanzapine concentrations, plasma 
glucose, plasma lipids, and lipogenic gene expression in 
liver and visceral adipose tissue. Furthermore, glucose and 
insulin tolerance tests were performed 12  months into the 
experiment. In addition, to determine whether the previously 
described lipogenic activation only occurs in young rats, we 
examined the effects of a first-ever olanzapine injection 
5 days prior to sacrifice in a subset of rats having been han-
dled as controls for 13 months. To the best of our knowledge, 
this is the first study to report on the long-term effects of 
olanzapine exposure in the rat.
Methods
Animals
All experiments were approved by and carried out in accord-
ance with the guidelines of the Norwegian Committee for 
Experiments on Animals (Forsøksdyrutvalget, FDU) with ID 
2015–7661. Female outbred Sprague-Dawley rats (Mollegaard, 
Denmark) were kept under standard conditions with an arti-
ficial 12:12-hour light/-dark cycle (lights on: 8:00 am) and con-
stant 48% humidity. Animals were housed 5 per cage during the 
experiment and allowed access to tap water and free (ad libi-
tum) access to standard laboratory chow (Special Diets Services, 
Witham, UK) during the experimental period. Rats were weighed 
regularly, while food intake was not measured in this experi-
ment. Care was taken to ensure minimal suffering of the ani-
mals at all stages of the experiments.
Significance Statement
Patients suffering from schizophrenia often receive treatment with so-called antipsychotic medication for extended periods of 
time. While dampening symptoms, this medication can also have side effects such as weight gain and diabetes. In trying to reveal 
how antipsychotics induce such side effects, rat models are frequently used, but experiments are often unrealistically short (1–2 
weeks). In this study, we tried to mimic the real-life situation, treating rats for over a year (corresponding to more than one-half 
of a rat’s life span) with the antipsychotic olanzapine. In spite of gaining extra weight and showing early signs of diabetes, overall 
the rats adapted surprisingly well to the treatment. Healthy rats may provide a less reliable model for antipsychotic-induced side 
effects, and replacing them with rodents more vulnerable to drug-induced side effects could increase the relevance for humans.
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Treatment Schemes
The experimental design is shown in Figure 1. Rats (n = 110) weigh-
ing 220 to 240  g at the start of the experiment received regular 
intramuscular injections of either commercially available long-
acting olanzapine pamoate formulation (100 mg/kg body weight 
[BW] ZypAdhera, Eli Lilly, IN) or vehicle solution (injection volume 
160 µL/250 g BW) for up to 13 months. A drug dose of 100 mg/
kg BW was chosen to reflect the amount of olanzapine received 
by patients exposed to LAI, which are approximately 15 times 
higher than oral formulations (Kane et al., 2010; Skrede et al., 
2014). From the start of the experiment, rats received injec-
tions every 10th day. In rats, an injection interval between 10 
to 14 days has previously been shown to reproduce metabolic 
effects observed in humans (Skrede et  al., 2014; Ferno et  al., 
2015; Horska et al., 2016). However, no published study has so far 
exposed rats to olanzapine LAI for more than 8 weeks (Horska 
et  al., 2016). When sedation and gradual weight loss  observed 
in the rats after more than 8 weeks of drug exposure (see the 
Results section for further information), we performed drug 
monitoring that disclosed very high olanzapine concentrations 
in plasma. The injection interval was subsequently increased to 
2.5 weeks (approximately 18 days) for the rest of the experiment. 
Olanzapine-treated animals (n = 10) and vehicle-treated animals 
(n = 10) were sacrificed 1, 3, or 6  months after the first injec-
tion (Figure 1a). For each of the 3 time points, rats received the 
last dose of vehicle or olanzapine 1 week prior to sacrifice and 
were fasted overnight to minimize potential variability in gene 
expression linked to differences in metabolic parameters. Due 
to the signs of possible drug toxicity (see above), samples from 
the 3-month time point were excluded from further analysis.
After 13  months, the remaining animals (n = 50) were split 
into 5 subgroups (Figure 1b). Vehicle-treated rats were either 
continuously treated with vehicle solution (n = 12) or received 
a first-ever injection of olanzapine pamoate (n = 14; olanzap-
ine subchronic group). Of these latter animals, one-half (n = 7) 
received chow ad libitum. The remaining animals (n = 7) were 
pair-fed, that is, the group of animals received an amount of 
chow corresponding to that consumed by the group of con-
trol animals during the previous 24 hours. A  time period of 
5 days was selected to represent a subchronic treatment period, 
based on previous rat experiments of gene expression (Saeedi 
et al., 2007; Ersland et al., 2015; Ferno et al., 2015; Ersland et al., 
2017). As for the animals already treated with olanzapine for 
13 months (n = 24), this group was divided into 1 ad libitum-fed 
group (n = 12) and 1 pair-fed group (n = 12). Six days after the 
last injection and group subdivision, rats were fasted overnight. 
Sacrifice was performed over 3 separate days (9 am–1 pm) but al-
ways 6 days after the last injection. All rats were randomized to 
time of sacrifice to avoid confounding effects.
Dissection, RNA Extraction, cDNA Synthesis, and 
Quantitative Real-Time PCR
Rats were anesthetized by isoflurane gas (Isoba vet, Schering-
Plough, Denmark) and subsequently sacrificed by decapitation. 
Upon sacrifice, selected organs were rapidly weighed before tis-
sue samples were harvested and flash frozen. Truncal blood col-
lected in EDTA tubes was centrifuged at 3000 g for 10 minutes 
(4°C) to extract plasma, which was stored at −80°C. Tissue sam-
ples (~20 mg of liver tissue or ~100 mg of adipose tissue) were 
homogenized using a TissueLyser (Qiagen, Hilden, Germany). 
RNA extraction was performed using an ABI Prism 6100 Nucleic 
Acid PrepStation (Applied Biosystems, Foster City, CA). DNase 
treatment was performed according to the manufacturer’s 
protocol. Quality and amount of total RNA were measured using 
Figure 1. Schematic overview of the experimental setup. The study initially included 56 control rats and 54 olanzapine-treated rats. (a) Long-acting injections (LAI) 
of olanzapine are indicated by vertical bars, and time points of sacrifice are illustrated by number of treatment months. Olanzapine-treated rats (n = 10) and vehicle-
treated rats (n = 10) were sacrificed at each indicated time point. (b) After 13 months of olanzapine treatment, the remaining 50 rats were subdivided into 5 groups: 
ad libitum-fed vehicle-treated rats (n = 12), ad libitum- and pair-fed (both n = 7) subchronic olanzapine-treated rats, and ad libitum- and pair-fed (both n = 12) chronic 
olanzapine-treated rats. Grey vertical bars illustrate LAI during the experiment, and the black arrow indicates the last injected dose.
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the NanoDrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). cDNA synthesis and quantitative real-time 
PCR (qPCR) were performed as previously described (Ferno et al., 
2009). Relative gene expression levels were determined using 
the comparative CT method, using β-actin and ribosomal protein 
lateral stalk subunit P0 as endogenous controls.
Plasma Measurements of Lipids, Glucose, and 
Olanzapine
Fasted glucose and lipid parameters (total cholesterol, HDL choles-
terol [HDL-C], LDL cholesterol [LDL-C], free fatty acids, phospho-
lipids, and triglycerides [TG]) in plasma samples from each time 
point were measured enzymatically using the Hitachi 917 system 
(Roche Diagnostics, Basel, Switzerland). Plasma levels of olanzap-
ine were determined by means of high performance liquid chro-
matography by the Agilent 1290 Infinity Binary LC coupled to an 
Agilent 6490A triple quadrupole mass spectrometer using positive 
electrospray ionization (Agilent Technologies, Santa Clara, CA).
Glucose and Insulin Tolerance Tests
After 12  months of treatment with either LAI olanzapine or 
vehicle and 1 week after the most recent injection, a subgroup 
of randomly selected olanzapine (n = 10) and vehicle (n = 10) rats 
underwent a glucose tolerance test (GTT). Blood glucose from 
all rats was measured before the initiation of the test (i.e., “fed” 
blood glucose). Rats were fasted for 2 hours, and blood glucose 
was measured once more (i.e., “fasted” blood glucose). After fast-
ing, the rats received 2 mg glucose per gram of total body mass 
by oral gavage. During the test, ~1 µL and ~20 µL whole blood was 
collected from the severed distal tip of the animal’s tail at 5 time 
points (0, 15, 30, 60, and 120 minutes). One µL was used for direct 
measurement of glucose level using a glucometer (Ascensia 
Contour, Bayer, Norway). For subsequent insulin level measure-
ments in plasma, 20 µL whole blood was collected in EDTA tubes, 
immediately centrifuged and 5 µL plasma was extracted and ana-
lyzed using an Ultrasensitive Rat Insulin ELISA kit (CrystalChem, 
Elk Grove Village, IL). To maintain animal well-being, the 2 tests 
were separated in time by 3 weeks. Two weeks after the GTT, rats 
received an intramuscular injection of olanzapine in accordance 
with the general treatment protocol. One week later, the same 
10 rats underwent an insulin tolerance test (ITT). Similar to the 
GTT, blood glucose was measured before the initiation of the test 
and after 6 hours of fasting. ITT was performed by i.p. injection of 
0.75 U insulin per kilogram of body weight (Actrapid, Denmark), 
blood was sampled at 0, 15, 30, 45, 60, 75, and 90 minutes, and 
blood glucose was measured as described for the GTT.
Statistical Analysis
Body weight gain was analyzed using repeated-measures ANOVA 
(SPSS statistics, SPSS Inc, Chicago, IL). Pearson’s correlation 
analysis and Kaplan-Meier survival analysis were performed in 
SPSS. All other analyses were performed in GraphPad Prism 8 
(GraphPad Software Inc., La Jolla, CA). Alteration in the composi-
tion of plasma lipids and glucose over time was assessed by lin-
ear regression. Results from glucose measurements during GTT 
and ITT were analyzed using 2-way repeated-measures ANOVA 
(with time and treatment as independent factors), using Sidak’s 
multiple comparisons test. Plasma insulin levels during GTT 
were analyzed using mixed-effects model due to 1 missing value. 
Alterations between fasted and fed blood glucose were analyzed 
by the 2-sided Student’s t test. For differential gene expression, 
statistical significance was determined by the 2-sided Student’s 
t test (when 2 groups were compared) or 1-way ANOVA (when 3 
groups were compared, i.e., subchronic groups) followed by post 
hoc Dunnett’s multiple comparisons test. Two-sided Student’s t 
test was used to assess alterations in liver and periovarian white 
adipose tissue (WAT) weights. Uncorrected- or Dunnett’s adjusted 
P values <.05 were considered significant. Data are reported as 
mean ± SEM.
Results
In the following, data for up to 13 months of olanzapine expo-
sure are presented. Initially, rats were exposed to LAI of olan-
zapine every 10th day. This dosing interval was chosen due to 
previous observations of weight gain during the first 10  days 
after olanzapine LAI injections, with subsequent deceleration of 
weight gain (Skrede et al., 2014; Ersland et al., 2015). However, 
after more than 8 weeks of exposure, rats gradually displayed 
signs of drug toxicity, with sedation, weight loss, and high olan-
zapine plasma concentrations. Based on these observations, 
blood and tissue samples from the 3-month time point were not 
included in the analyses. For purposes of clarity, data from rats 
treated subchronically (i.e., for 5  days) with olanzapine in the 
final stages of the 13-month experiment are presented sepa-
rately at the end of the results section.
Body Weight Gain in Olanzapine-Treated Rats 
Sustained Throughout the Experiment
Average body weight in the 2 groups was similar at baseline 
(average ± SEM: control group, 235.6 ± 0.48  g; olanzapine group, 
237.1 ± 1.2 g; P value: n.s.). Rats receiving injections of olanzapine 
every 10th day rapidly gained more weight than control animals 
(Figure 2). More than 8 weeks into the experiment, clinically 
obvious sedation in olanzapine-treated rats coincided with pro-
nounced, unexpected weight loss (Figure 2). Blood samples from 
a selection (n = 10) of the rats showed very high plasma olanzap-
ine levels (234.6 ± 73.9 ng/mL). Due to poor sample quality, these 
results have to be regarded as uncertain, but correspondingly 
high plasma olanzapine levels were likely present in many of 
the rats at this stage of the experiment. After a period of 5 weeks 
without further injections, sedation and weight loss receded 
and treatment was re-initiated, followed by injection interval 
adjusted to approximately 2.5 weeks (18  days). Subsequent to 
this adjustment, that is, from approximately day 90, each olan-
zapine injection was generally followed by a short period of 
accelerated weight gain, which then decelerated, followed by 
renewed increase in body weight gain after the next injection 
(Figure 2). As expected, control rats gained weight throughout 
the experiment. Cumulative body weight gain in the control and 
olanzapine treatment groups remained statistically different 
throughout the entire experiment (repeated-measures ANOVA).
Equal Long-Term Mortality in Control and 
Olanzapine-Exposed Rats
Kaplan-Meier survival analysis showed no significant differ-
ence in mortality between vehicle-treated rats and rats treated 
with olanzapine during the 13-month experiment (supplemen-
tary Figure 1). One olanzapine-treated rat died spontaneously 
3 weeks after the initiation of treatment, with postmortem 
examination revealing signs of paralytic ileus (supplemen-
tary Figure 1). Age-related adenomas are common in the rat 
and occurred with equal prevalence in control rats (n = 6) and 
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olanzapine-treated rats (n = 5) in our study (Okada et al., 1981). 
Rats developing adenomas were euthanized.
Plasma Concentrations of Olanzapine
In the 10 olanzapine-treated rats sacrificed after 1  month of 
treatment, that is, 1 week after a third intramuscular injection 
of olanzapine, the average plasma concentration of olanzap-
ine was 59.5 ± 9.8 ng/mL (Table 1). At 6 months the concentra-
tion was 25.1 ± 2.1 ng/mL, while at 13 months it had increased 
to 84.8 ± 7.9 ng/mL. Former control rats administered with olan-
zapine for the first time 5 days prior to sacrifice at the 13-month 
time point (subchronic group) had an average plasma olan-
zapine concentration of 18.0 ± 2.2 ng/mL (all rats, independent 
of nutritional status). With the exception of the subchroni-
cally exposed rats, where plasma olanzapine was relatively 
low, plasma concentrations at all other time points (1, 6, and 
13 months) remained within a range described as therapeutic 
and nontoxic in humans (i.e., 22.77 ≥ 100 ng/mL) (Robertson and 
McMullin, 2000; Lu et al., 2016; Tveito et al., 2018).
Olanzapine Does Not Increase Plasma Lipids or 
Glucose in the Long Term
Plasma lipids (free fatty acids, TG, phospholipids, total choles-
terol, LDL-C, and HDL-C) and plasma glucose were measured 
at each time point of sacrifice (1, 6, and 13 months). As previ-
ously described, linear regression analysis revealed that levels 
of phospholipids and cholesterol increased with age in both 
olanzapine- and vehicle-exposed animals (Table 2a–b; supple-
mentary Figure 2) (Uchida et al., 1978). Levels of TG increased 
only in olanzapine-exposed animals, while HDL-C increased 
only in control animals, over time. Contrary to our expecta-
tions, plasma lipids were not further increased after long-term 
olanzapine treatment compared with control rats. The only 
observed alteration was a lower amount of plasma LDL-C in 
olanzapine-exposed animals, compared with controls, after 
1  month of treatment (2-sided Student’s t test, uncorrected 
P value: <.05) (Table 2). Levels of plasma glucose in olanzap-
ine-exposed rats significantly decreased over time, whereas 
control animals did not show any alteration (Table 2c; supple-
mentary Figure 2).
GTT and ITT at 12 Months: Olanzapine-Induced 
Hyperinsulinemia
A subgroup of vehicle-treated (n = 10) and olanzapine-treated 
(n = 10) rats underwent a separate GTT and ITT 1 week after the 
last injection, approximately 12  months into the experiment. 
Fasted or fed blood glucose was not different between vehicle- 
and olanzapine-treated rats (2-sided Student’s t test, uncor-
rected P value: n.s.) (Figure 3a).
Using 2-way repeated-measures ANOVA, time was found to 
have the main effect on glucose levels in rats during the GTT 
(F(2.303,41.45) = 60.24, P <.0001) (Figure 3b), regardless of whether 
they were exposed to olanzapine. Further analysis using Sidak’s 
multiple comparisons test revealed no significant difference 
between the 2 groups, which was also evident from the area 
under the curve (AUC) (Figure 3c).
In accordance with the glucose measurements, time was 
also found to be the main effector on insulin levels in plasma 
taken during the GTT (F(2.256,40.05) = 33.53, P <.0001), while 
treatment had no apparent effect (Figure 3d). Using Sidak’s mul-
tiple comparisons test, significantly higher plasma insulin was 
found in olanzapine-treated rats compared with vehicle-treated 
Figure 2. Cumulative body weight gain. Average weight gain in grams (± SEM). Data for all rats alive at any given time point are included. Note that for each time point 
where rats were sacrificed (marked with †), these rats were eliminated from the weight estimates. A drop in cumulative weight gain for olanzapine-exposed animals 
can be observed around day 75, due to possible signs of toxicity, e.g., sedation. Repeated-measures ANOVA was used to analyze differences in cumulative body weight 
gain between olanzapine- and vehicle- exposed animals: ***P ≤ .001, compared with vehicle.
Table 1. Plasma Olanzapine Concentrations
Treatment Group Plasma Olanzapine (ng/mL)
1 month 59.5 ± 9.8
6 months 25.1 ± 2.1
13 months chronic 84.8 ± 7.9
13 months subchronic ad lib 18.8 ± 2.6
13 months subchronic pair-fed 17.2 ± 3.6
Plasma olanzapine measures are given as average ± SEM ng/mL. ad lib, ad libi-
tum; subchronic, 5-day treatment. 
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rats 60 and 120 minutes after an oral glucose load (P = .0376 and 
.0286, respectively), indicating that olanzapine-treated rats were 
hyperinsulinemic.
During the ITT, 2-way repeated-measures ANOVA revealed 
that both time (F(2.018,36.32) = 33.21, P <.0001) and treatment 
(F(1,18) = 4.675, P = .0443) significantly affected glucose levels in the 
rats (Figure 3e). Furthermore, an interaction effect was observed 
between time and treatment (F(6, 108) = 3.114, P = .0075), indicat-
ing that olanzapine exposure had an effect on glucose levels over 
time. This was also reflected at 60 and 75 minutes, where olanzap-
ine-exposed rats had significantly higher blood glucose levels than 
vehicle-treated rats (Sidak’s multiple comparisons test P =  .0354 
and .0195, respectively) and in an increased AUC (Figure 3f).
Increased Liver and Periovarian WAT Weights at 
1 Month
At each time point of sacrifice (1, 6 ,and 13 months), liver and 
periovarian WAT were weighed, with the addition of skeletal 
muscle tissue (gastrocnemius muscle) at 13  months. For pur-
poses of comparison, data at 13 months include ad libitum-fed 
rats only. At 1  month, liver and periovarian WAT weights (in 
percentage of body weight) were significantly higher in olan-
zapine-treated rats than vehicle rats (2-sided Student’s t test, 
uncorrected P = ≤.05 and .001, respectively) (Figure 4a–b). At the 
later time points, this was not the case. At 13 months, cumula-
tive body weight gain was positively correlated with periovarian 
WAT weight (Pearson’s correlation analysis, r = 0.58, P = .04), but 
not with relative weight of the liver or gastrocnemius muscle 
(data not shown).
Transiently Increased Expression of Genes Encoding 
Lipid Biosynthesis Enzymes
The expression of lipogenic genes in liver and periovarian WAT 
was examined using qPCR. At 1 month, hepatic transcription of 
the key lipogenic genes Acetyl-CoA carboxylase 1 (Acc1), Fatty acid 
synthase (Fasn), and HMG-CoA reductase (Hmgcr) was upregulated 
approximately 2-fold in olanzapine-treated rats compared with 
control rats (2-sided Student’s t test, uncorrected P = .024, .033, 
and .022, respectively) (Figure 5a–c). A similar upregulation was 
not found in periovarian WAT (Figure 5d–f). At the later time 
points, no transcriptional differences were found between the 
treatment groups in these tissues (Figure 5).
Lipogenic Activation After Subchronic Exposure to 
Olanzapine in Older Control Rats
Subchronic (5-day) treatment with olanzapine did not result in 
alterations of plasma lipid levels or organ weights in rats that 
had previously been part of the vehicle-treated group for more 
than 12 months (data not shown). The short-term treatment did, 
however, significantly affect the transcription of selected lipo-
genic genes both in liver and periovarian WAT. In the liver, Acc1 
and Hmgcr expression levels were significantly upregulated by 
olanzapine in the pair-fed group (Dunnett’s adjusted P =  .0001 
and .0022, respectively) (Figure 6a,c), while expression of Fasn 
was unaffected (Figure 6b). No upregulation was observed in the 
liver in the ad libitum-fed group. In periovarian WAT, the Fasn 
level was upregulated, most prominently in the ad libitum-fed 
rats (Dunnett’s adjusted P = .0081) (Figure 6e). Expression of Acc1 
and Hmgcr was unaltered by olanzapine treatment in this tissue, 
regardless of feeding regime (Figure 6d,f).
Discussion
We performed a 13-month experiment, which to our know-
ledge constitutes the most extensive exposure to olanzapine 
described in the rat in an academic setting. Comparing the life-
span of rats to that of humans, 2 weeks of a rat’s life corresponds 
to approximately 1 human year (Sengupta, 2013). According to 
Table 2a. Composition of Plasma Lipids: Free Fatty Acids, Triglycerides, and Phospholipids
Month FFA TG PL
 VEH OLZ VEH OLZ* VEH*** OLZ***
1 0.47 ± 0.04 0.46 ± 0.06 0.56 ± 0.03 0.66 ± 0.10 1.86 ± 0.08 1.98 ± 0.06
6 0.70 ± 0.04 0.63 ± 0.09 1.64 ± 0.25 1.08 ± 0.21 2.76 ± 0.18 2.46 ± 0.10
13 0.55 ± 0.06 0.55 ± 0.06 1.19 ± 0.17 1.43 ± 0.32 3.14 ± 0.06 2.76 ± 0.06
Table 2b. Composition of Plasma Lipids: Cholesterol
Month TC HDL-C LDL-C
 VEH*** OLZ*** VEH*** OLZ VEH** OLZ***
1 2.08 ± 0.12 2.08 ± 0.10 1.89 ± 0.12 1.91 ± 0.09 0.31 ± 0.03 0.21 ± 0.02#
6 2.96 ± 0.28 2.62 ± 0.13 2.08 ± 0.09 2.20 ± 0.10 0.25 ± 0.03 0.28 ± 0.02
13 3.45 ± 0.24 2.95 ± 0.18 2.58 ± 0.12 2.19 ± 0.09 0.54 ± 0.12 0.38 ± 0.04
Table 2c. Plasma Levels of Glucose
Month Glucose
 VEH OLZ***
1 7.90 ± 0.23 8.81 ± 0.30
6 8.10 ± 0.17 8.43 ± 0.18
13 8.04 ± 0.18 7.38 ± 0.23
Abbreviations: FFA, free fatty acids; HDL-C, HDL-bound cholesterol; LDL-C: LDL-
bound cholesterol; OLZ, olanzapine-treated rats; PL, phospholipids; TG, triglyc-
erides; VEH, vehicle-treated rats. 
Measurements of plasma lipids and glucose (mean ± SEM, mmol/L). 
Linear regression analysis was used to assess change over time in the lipid 
parameters and glucose measurements: *P ≤ .05, **P ≤ .01, ***P ≤ .001. Alterations 
in lipid parameters and glucose levels at 1, 6, or 13 months, between VEH and 
OLZ animals, were assessed by the Student’s t test; # uncorrected P <.05.
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this estimate, rats sacrificed at 13 months had been treated with 
olanzapine for what would amount to 26 human years.
The pharmacokinetics of olanzapine LAI in the rat is 
largely unknown. An olanzapine dose of 100  mg/kg was 
chosen due to the fact that patients treated with olanzapine 
LAI receive doses approximately 15 times as high as patients 
treated with oral formulations (Kane et  al., 2010). We and 
others have previously observed hyperphagia and weight 
gain in female rats treated with oral administration of 5 to 
10  mg/kg olanzapine daily (Goudie et  al., 2002; Kalinichev 
et al., 2005; Skrede et al., 2012b). The chosen dose of 100 mg/
kg corresponds to a daily dose of 6.67 mg/kg multiplied by 15.
Repeated administration of olanzapine LAI 100 mg/kg every 
10th day initially resulted in rapid and sustained body weight 
Figure 3. Glucose and insulin tolerance. Glucose and insulin tolerance tests (GTT/ITT) were performed 3 weeks apart in the same rats treated either with vehicle (VEH; 
n = 10) or olanzapine LAI (OLZ; n = 10). (a) Fed and fasted blood glucose was measured from whole blood before and after a 2- (GTT) or 6- (ITT) hour fast, respectively. 
(b) GTT showing whole blood glucose concentrations during the first 2 hours after administration of 2 mg glucose per gram of total body mass by oral gavage. (c) Area 
under the curve (AUC) calculated from blood glucose concentrations during the GTT. (d) Plasma insulin concentrations during the GTT. (e) ITT showing blood glucose 
during the first 90 minutes after an i.p. injection of 0.75 U/kg BW insulin. (f) AUC calculated from blood glucose concentrations during the ITT. Statistically significant 
change between fasted and fed blood glucose was assessed using the 2-sided Student’s t test. Two-way repeated-measures ANOVA or mixed-effects model, and Sidak’s 
multiple comparison test was used to analyze the glucose measurements during the GTT and ITT, in addition to insulin measurements taken during the GTT. * P ≤ .05.
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gain, as previously described (Skrede et al., 2014; Horska et al., 
2016). However, as treatment continued using injections every 
10th day, a gradual cessation in weight gain appeared. Previous 
studies have only analyzed the effects of LAI of olanzapine 
(injections every 10th–14th day) for up to 8 weeks. Following 
almost 3  months of drug exposure, the selected treatment 
scheme resulted in very high plasma olanzapine levels. It is 
likely that frequent LAI led to accumulation of olanzapine 
Figure 5. Expression of genes encoding rate-limiting lipogenic enzymes in liver and periovarian white adipose tissue. At each time point, quantitative real-time PCR 
(qPCR) was performed. Fold change is expressed relative to vehicle, which is always normalized to 1. Fold changes are given as mean ± SEM. Acc1, acetyl-CoA carboxy-
lase 1; Fasn, fatty acid synthase; Hmgcr, HMG-CoA reductase. The 2-sided Student’s t test was used to assess statistically significant alterations in expression levels: 
*uncorrected P ≤ .05, compared with vehicle.
Figure 4. Liver and periovarian white adipose tissue weight. Weights are given as percentage body weight (±SEM) at the 4 different time points of sacrifice. OLZ, olan-
zapine; VEH, vehicle. Data for ad libitum-fed olanzapine-treated rats are shown at 13 months. The 2-sided Student’s t test was used to assess statistically significant 
alterations in weight: *uncorrected P ≤ .05, ***uncorrected P ≤ .001, compared with vehicle.
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over time, resulting in toxic effects and arrested weight gain. 
As a consequence of this situation, the injection rate was 
decreased to every 18th day, which subsequently resulted in 
reappearance of weight gain. Notably, at 1, 6, and 13 months, 
plasma levels of olanzapine were within the range measured 
in postmortem and therapeutic drug monitoring samples 
(Robertson and McMullin, 2000; Lu et  al., 2016; Tveito et  al., 
2018). According to clinical recommendations, therapeutic 
drug monitoring samples during olanzapine LAI treatment are 
drawn at an estimated trough value 0 to 2 days before the next 
scheduled injection (10–28 days after the last injection). In the 
rats, samples were taken approximately 7 days after the last 
injection. Thus, plasma levels in the rats are not trough lev-
els and thus not directly comparable with data from patients. 
Bearing this and other limitations of a direct comparison be-
tween rats and humans in mind, the measured plasma levels 
of olanzapine combined with the reappearance of weight gain 
during the subsequent stages of the experiment nevertheless 
indicate that the animals were not subject to toxic carryover 
effects during the remaining experimental period.
In the event of a new, similar study, the data from the present 
experiment should nevertheless lead to consideration of lower 
doses or an increased injection interval. Considering exam-
ples from experiments involving osmotic minipumps, a dosing 
regimen based on dopamine D2 receptor occupancy should be 
developed (Kapur et al., 2003).
 In spite of significant weight gain, olanzapine treatment 
did not result in significant elevation of plasma lipids or fasting 
glucose throughout the experiment. This is in agreement with a 
recent study performed by Horska et al., where a lack of altera-
tion in serum lipids at 4 separate time points during a 2-month 
experiment in female rats treated with olanzapine LAI was 
demonstrated (Horska et al., 2016). One possible cause for the 
lack of plasma lipid increase could be the presence of various 
homeostatic feedback mechanisms. In an acute setting, with 
regular measurements from 30 minutes until 48 hours after a 
single dose of olanzapine or clozapine, we previously described 
an initial, potent transcriptional increase in genes involved in 
lipid and carbohydrate biosynthesis, followed by marked com-
pensatory downregulation (Ferno et al., 2009; Jassim et al., 2012). 
Figure 6. Expression of genes encoding rate-limiting lipogenic enzymes in liver and periovarian white adipose tissue 5 days after a first-ever injection of olanzapine 
LAI in rats treated as controls for 12.5 months. Acc1, acetyl-CoA carboxylase 1; Fasn: fatty acid synthase; Hmgcr: HMG-CoA reductase; OLZ ad lib: olanzapine-treated rats 
with free access to chow; OLZ pair-fed: olanzapine-treated rats with restricted access to chow; VEH, vehicle. Fold changes are given as mean ± SEM. One-way ANOVA, 
followed by Dunnett’s multiple comparisons test, was used to assess statistical significance. **Dunnett’s adjusted P ≤ .01, ***Dunnett’s adjusted P ≤ .001.
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Similar processes may be in operation during long-term drug 
exposure. Of note, in the present experiment separate cohorts 
of rats were sacrificed and sampled at each time point, and this 
may have influenced results. Ideally, the same rats should have 
been sampled at each time point, but this would limit plasma 
volume available for analysis and would not allow for tissue 
sampling.
After 1 month of treatment, but not at the later time points, 
hepatic expression of the rate-limiting lipogenic genes Acc1, 
Fasn, and Hmgcr was upregulated by olanzapine. Corresponding 
upregulation was observed in a subchronic context in treat-
ment-naïve, 13-month-old rats that received their first-ever 
injection of olanzapine, but not 7 days after the last injection in 
rats having already been treated with olanzapine for 13 months. 
These results illustrate 2 points. First, while the majority of 
previous experiments have been performed in very young rats, 
young age is not a prerequisite for rats to be sensitive to the 
dysmetabolic potential of olanzapine. Secondly, long-term treat-
ment diminished the lipogenic transcriptional response, which 
could be interpreted as a sign of desensitization to the lipogenic 
effects of olanzapine.
Notably, the upregulation of lipogenic genes was not accom-
panied by increased plasma lipids. Acc1, Fasn, and Hmgcr are 
involved in the early stages of fatty acid and sterol metabolism. 
To understand the full lipogenic impact of olanzapine in the 
liver and adipose tissues, transcription of downstream genes 
in complex lipid and lipoprotein biosynthesis and assembly 
should be examined, in addition to analyses of relevant protein 
and lipid levels.
In contrast to the analyses performed on dissected tissues, 
GTT and ITT were performed in vivo. After 1 year of olanzap-
ine LAI treatment, these tests demonstrated the presence of 
olanzapine-induced hyperinsulinemia and pointed towards 
a reduction in insulin sensitivity, supported by the lack of 
increased fasting glucose levels in olanzapine-treated rats dur-
ing the experiment. The association between olanzapine treat-
ment and type 2 diabetes is well established in patients (Correll 
et al., 2017). The propensity to induce diabetes is correlated with 
affinity to muscarinic 3 receptors and could be due to inhibited 
insulin secretion, but several pathophysiologic mechanisms 
have been suggested (Reynolds and Kirk, 2010). In animal mod-
els, findings of glucose intolerance with concomitant decrease 
in insulin sensitivity and/or increased hepatic gluconeogenesis 
have been reproduced in short-term experiments with olan-
zapine as well as other atypical antipsychotics (Houseknecht 
et al., 2007; Chintoh et al., 2008). The GTT/ITT performed dur-
ing this experiment did not allow us to determine the cause of 
hyperinsulinemia, but clearly demonstrated that the metaboli-
cally unfavorable olanzapine effects previously demonstrated in 
short-term experiments were also present at this chronic stage 
of treatment.
The choice of healthy rats as a model system may have 
influenced our findings, both with regard to metabolic disrup-
tion and major psychotic disorders. Lipid metabolism differs 
significantly in humans and rats, leaving rats far less vulnerable 
to dyslipidemia and atherosclerosis (Russell and Proctor, 2006). 
Dietary modification or use of genetically modified rodents are 
frequently used in animal studies on the metabolic syndrome 
(Aleixandre de Artinano and Miguel Castro, 2009). Psychotic dis-
orders are also notoriously difficult to model in rodents, with 
pharmacological models potentially interfering with the effects 
of, for example, antipsychotic agents. Other approaches, such as 
the neurodevelopmental polyI:C model, have been successfully 
employed to examine metabolic effects of the antipsychotic 
agent aripiprazole (Horska et al., 2017). The use of rats with a 
propensity to metabolic disruption and/or phenotypes reminis-
cent of schizophrenia would clearly increase the translational 
impact of experiments.
The choice of outcomes is also likely to have affected our 
results. In previously published studies, the use of functional 
testing such as oral lipid tolerance tests and isoproterenol chal-
lenges to examine lipolytic capacity has enhanced the under-
standing of metabolic derangements induced by short-term 
olanzapine exposure (Albaugh et  al., 2011, 2012). As demon-
strated through the GTT/ITT procedures performed during our 
experiment, metabolic challenges may also yield a more com-
prehensive impression of metabolic functioning during long-
term treatment with olanzapine and should be included in 
future experiments.
To conclude, future experiments should include improved 
dosing regimens and ideally be performed in rats with pheno-
types relevant for metabolic or psychiatric disorders. In addition, 
a true longitudinal design, with samples taken from the same 
rats at several time points, would be valuable. Finally, findings 
should be validated in the male rat. Still, bearing these limita-
tions in mind, this work clearly shows that the use of olanzapine 
LAI in female rats facilitates long-term experiments, overcoming 
some of the previous obstacles in the field. Substantial weight 
gain, with accompanying signs of hyperinsulinemia, was main-
tained throughout the 1-year treatment period. Furthermore, in 
vivo tests supported the presence of reduced insulin sensitiv-
ity. The results from this proof-of-principle experiment could 
facilitate further unravelling of the molecular underpinnings of 
olanzapine-induced metabolic adverse effects.
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